Barclays Maintains Equal-Weight on Alcon, Raises Price Target to $80
Barclays analyst Christopher Pasquale maintains Alcon (NYSE:ALC) with a Equal-Weight and raises the price target from $70 to $80.
Follow the latest Alcon Inc. (ALC) news and market headlines alongside the live ALC price. Stay informed on what's moving ALC.
Barclays analyst Christopher Pasquale maintains Alcon (NYSE:ALC) with a Equal-Weight and raises the price target from $70 to $80.
Baird analyst Jeff Johnson maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $90 to $87.
Analysts cut targets and ratings for General Mills, Redwood Trust and Evgo, while raising targets for Radcom, Royal Caribbean and others.
Stifel analyst Thomas Stephan maintains Alcon (NYSE:ALC) with a Hold and lowers the price target from $70 to $65.
Alcon reported Q3 2026 earnings with ~6% full-year net sales growth guidance and double-digit core EPS growth. The company is defending its premium intraocular lens market share against competitors through new products (Vivity Pro, TruPlus), expanding UNITY surgical equipment placements to 40% of U.S. teaching hospitals, and acquiring Neurotech Pharmaceuticals for retinal disease treatment with peak sales potential of $250-400 million. Management emphasized outpacing the 3% baseline eye care market growth through operational efficiency and margin expansion.
Alcon Inc. (ALC) reported Q3 2026 core EPS of 91 cents, beating estimates by 2.3%, but net sales of $2.72 billion missed consensus by 0.6%. While Vision Care and Equipment segments showed strength, Implantables sales declined 2% due to competitive pressures. The company narrowed its 2026 guidance, expecting 6% constant-currency net sales growth and 12-14% core EPS growth, which weighed on investor sentiment.
News and data on this page is provided by our partnered third-party news and market data provider, with the original publisher credited on each article. All third-party content reflects the views of the original publisher and does not represent the views of MEXC. Price and market data shown on this page are provided by third-party data providers and may be delayed. MEXC offers trading products related to ALC, including RealStocks and Stock Futures.
The content on this page is provided for informational purposes only and does not constitute investment, financial, or trading advice. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of any news or market data shown. Trading U.S. stocks and related products involves significant risk, and prices can move sharply in a short period. Past performance does not guarantee future results. Please conduct your own research and assess your financial situation and risk tolerance before making any investment decisions. MEXC is not liable for any losses arising from the use of this information.